CANCIDAS Drug Patent Profile

✉ Email this page to a colleague

When do Cancidas patents expire, and when can generic versions of Cancidas launch?

Cancidas is a drug marketed by Merck and is included in one NDA.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cancidas

A generic version of CANCIDAS was approved as caspofungin acetate by FRESENIUS KABI USA on December 30^th, 2016.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for CANCIDAS?
What are the global sales for CANCIDAS?
What is Average Wholesale Price for CANCIDAS?

Summary for CANCIDAS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	19
Patent Applications:	2,361
Drug Prices:	Drug price information for CANCIDAS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CANCIDAS
What excipients (inactive ingredients) are in CANCIDAS?	CANCIDAS excipients list
DailyMed Link:	CANCIDAS at DailyMed

Drug patent expirations by year for CANCIDAS

Recent Clinical Trials for CANCIDAS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cidara Therapeutics Inc.	Phase 3
Cttq	Phase 2
Cidara Therapeutics Inc.	Phase 2

See all CANCIDAS clinical trials

Pharmacology for CANCIDAS

Drug Class	Echinocandin Antifungal

Paragraph IV (Patent) Challenges for CANCIDAS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANCIDAS	for Injection	caspofungin acetate	50 mg/vial and 70 mg/vial	021227	1	2009-06-26

US Patents and Regulatory Information for CANCIDAS

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CANCIDAS

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CANCIDAS

See the table below for patents covering CANCIDAS around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	1132624		⤷ Sign Up
Algeria	2205	Compositions antifongiques.	⤷ Sign Up
Hungary	9901586		⤷ Sign Up
Bulgaria	102857		⤷ Sign Up
Germany	10299013		⤷ Sign Up
Germany	69421639		⤷ Sign Up
Latvia	12574	AZA CIKLOHEKSAPEPTĪDI (AZA CYCLOHEXAPEPTIDE COMPOUNDS)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for CANCIDAS

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	01C0054	France	⤷ Sign Up	PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
0620232	SPC/GB02/002	United Kingdom	⤷ Sign Up	A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232	SPC/GB02/002 200210	United Kingdom	⤷ Sign Up
0620232	C300076	Netherlands	⤷ Sign Up	PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232	44/2001	Austria	⤷ Sign Up	PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
0620232	SPC029/2001	Ireland	⤷ Sign Up	SPC029/2001: 20031204, EXPIRES: 20161023
0620232	CA 2002 00007	Denmark	⤷ Sign Up
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description